Source: Indianapolis Business Journal

FAST BioMedical: Fast BioMedical achieves clinical endpoints with plasma technology

The Carmel startup said its midstage clinical trials met key objectives, an achievement that will it allow to continue developing a technology that measures blood volume and kidney function.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Joe Muldoon's photo - CEO of FAST BioMedical

CEO

Joe Muldoon

CEO Approval Rating

70/100

Read more